drugset / Trial / NCT03274206

A Trial to Evaluate the Efficacy and Safety of BLS-ILB-E710c in Patients With Cervical Intraepithelial Neoplasia 2/3 (CIN2/3)

NCT03274206 ↗

Phase 2 Unknown 126 enrolled BioLeaders Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates the efficacy and safety of the experimental drug, BLS-ILB-E710c, in patients with Cervical Intraepithelial Neoplasia 2/3 (CIN2/3). 2/3 of participants will receive the experimental drug, while 1/3 of participants will receive placebo.

Timeline

Start
2017-08-30
Primary completion
2020-08
Completion
2020-08

Drugs

EvaluationDrugModalityDoseRoute
Subject BLS-ILB-E710c Unknown 1000 mg —